The Real Genetics Behind Zombie-Movie “Immunity”

Every outbreak movie and show has one: the person who was never going to get infected. World War Z has them. The Last of Us has them. It's always framed as this rare, almost magical thing — some people's bodies just don't let the pathogen in.

That part is fiction. But a real deletion in a real human gene gets closer to exactly that premise than almost anything else in genetics — for one specific, real virus, in real people, alive right now.

What the deletion actually does

HIV-1 doesn't just walk into a cell. To infect a CD4 T cell, most circulating HIV-1 has to grab onto a docking protein called CCR5 first — think of it as the door handle the virus needs before it can get in.

CCR5-delta32 is a 32-letter chunk of the CCR5 gene that's simply missing. Not a typo, not a single swapped letter — a whole piece gone. The result is a broken, truncated protein that never makes it to the cell surface. No working door handle, no easy way in for the strains of HIV-1 that need it.

People with two copies of this deletion have essentially no functional CCR5 on their immune cells. Because most HIV-1 circulating worldwide depends on that exact door handle, these people are strongly resistant to infection by it — including after repeated high-risk exposure. One copy is a different, smaller story: still infectable, but disease tends to progress 2 to 3 years more slowly.

The catch that ruins the movie plot

Here's where the zombie-movie comparison falls apart, and it's the most important part of the real story. A minority of HIV-1, usually later in untreated infection, switches to a different door handle entirely (called CXCR4) — and CCR5-delta32 does nothing to stop that version. People with two copies of the deletion have still been infected by it. It also says nothing about any other sexually transmitted infection, and obviously nothing about any pathogen that doesn't exist. Real biology is specific in a way movie immunity never has to be.

The real-world proof

This isn't just theoretical. In 2007, a man living with HIV-1 who also had leukemia — later known publicly as the "Berlin patient" — received a bone marrow transplant to treat his cancer. His doctors deliberately picked a donor who carried two copies of CCR5-delta32, hoping it might help his HIV too. It did: once his immune system was rebuilt from CCR5-less donor cells, he was able to stop HIV medication entirely and stayed free of detectable virus for years. In 2019, a second person — the "London patient" — achieved the same outcome with a less intensive version of the procedure, proving the first case wasn't a fluke.

Nobody is suggesting a bone marrow transplant as an HIV treatment plan — the procedure itself is serious and was done to treat life-threatening cancer, not simply to remove CCR5. But it's real, published proof that taking this one door handle away can produce exactly the kind of durable outcome outbreak fiction only pretends to explain.

Who actually carries it

CCR5-delta32 shows up on roughly 1 in 10 chromosomes across European populations — a bit more common in northern and eastern Europe — and is rare to essentially absent in sub-Saharan African, East Asian, and Indigenous American populations. Every known copy traces back to a single original deletion event, spread since by ordinary population history rather than arising independently again and again. Why it became common enough to study at all — what historical pressure favored carrying it — is still genuinely debated among researchers, which is its own interesting rabbit hole for another day.

The full, cited breakdown — genotype by genotype, including exactly which HIV-1 strains it does and doesn't stop — is on the CCR5-delta32 condition page.